2015 ASCO 肝胆肿瘤王凯峰.pptVIP

Slide 26 Presented By Ghassan Abou-Alfa at 2015 ASCO Annual Meeting Phase III Tivantinib vs Placebo NCPresented By Ghassan Abou-Alfa at 2015 ASCO Annual Meeting 5 yr HCC survival rate comparison; supports compulsive surveillance program Presented By Robert Gish at 2015 ASCO Annual Meeting 谢谢大家聆听 Regional therapy in HCC as a method to augment the immune response Presented By Ghassan Abou-Alfa at 2015 ASCO Annual Meeting HCC临床试验研究的二线全身治疗包括布立尼布（Brivanib ）、依维莫司（Everolimus ）、Ramicurumab、聚乙二醇化精氨酸脱亚胺酶（ADI-PEG20）、卡博替尼（Cabozantinib）、Tivantinib ADI-PEG20的作用机制为可将精氨酸降解为瓜氨酸，而HCC等肿瘤不能合成精氨酸。Ⅲ期试验纳入